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THE relation between malignancy and serum glycoproteins has been studied by
many workers. Shetlar, Foster, Kelly, Shetlar and Everett (1949) found that in a
series of 105 malignancies the serum glycoprotein was raised in 96% of cases.
Seibert, Seibert Atno and Campbell (1947) obtained similar results. Israel,
Webster, and Maher (1949) also found that the serum glycoproteins were elevated
in malignancy as well as in other diseases such as chronic infections. rheumatic fever,
lhyperthyroidism, hepatic disease and in pregnancy. Abd El-Ghaffar, Awny and
Abd El-Meguid (1961. unpublished data) also worked on a large series ofmalignant
cases and found that the serum glycoprotein level was raised in almost all cases,
though the degree of rise varied in different types of malignancy.
Shetlar, Erwin and Everett (1950) working on rats bearing the Walker 256
carcinoma reported that the total non-glucosamine polysaccharide level in the
serum increased as the tumour increased in size. Macbeth and Bekesi (1964)
worked on the seromucoid fraction in the serum of rats bearing Walker 256
carcinoma and by means of serial analyses of its protein, hexosamine, hexose,
sialic acid and fucose content, reported that all seromucoid components show a
p)rogressive and marked increase in the serum, and that the seromucoid produced
in response to aggressive tumour growth was chemically different as regards its
carbohydrate composition. Harshman and Bryant (1964) found that the chro-
matographic behaviour of serum mucoproteins in animals bearing Walker 256
carcinoma differed significantly from those of normal serum. Weimer, Quinn,
Redlich-Moshin and Nishihara (1957) also worked on male rats implanted with
Wtalker 256 carcinoma and by serial determinations found a highly significant
increase in the seromucoid fraction in the serum of animals with well established
tumours with coincident decline in other glycoproteins, total serum protein,
haemoglobin concentrations and haematocrit. Burston, Apsey and Maclagan
(1965) reported a high level of serum glycoprotein in tumour-bearing rats together
with increase in weight of liver and in its perchloric acid soluble protein, which
reached a maximum on the thirteenth day after implantation.
In the present work serial estimations of serum glycoprotein levels were made
in mice before, and at intervals after inoculation with sarcoma 180 and Ehrlich's
ascites tumours, till the death of the animals from the tumours.
MATERIALS AND METHODS
Animnals.-Ordinary Swiss mice were used, 8-12 weeks old.
Inoculation.-Sarcoma 180 was kindly supplied by N.C.I., Bethesda, Mary-
land. U.S.A., and was maintained by weekly transfer. The 7-day-old tumour was
aseptically removed, cut into small fragments, each about 1 mm. diameter; oneY. ABD EL-GHAFFAR AND S. ASSAD
fragment was inoculated subcutaneously into the mouse near the axilla by a
special needle.
Ehrlich's ascites tumour was also supplied by N.C.I. To inoculate the animal
with the tumour, 01 ml. of the ascitic fluid containing about 1,000,000 cells was
injected intraperitoneally.
Blood sampling.-Blood was withdrawn from the retrobulbar plexus into a
glass pipette of 3 mm. internal diameter and 5 cm. length, with one end curved
and attenuated into a capillary, and with a rubber sucker fixed to the other end.
This pipette allowed us to take about 0-2 ml. of blood by introducing the curved
capillary end behind the eye of the animal and sucking the blood. This method
caused no ill effects or fatalities to the mice and many samples could be taken from
the same animals on different days.
Measurements. The tumours were measured by multiplying the longest
diameter by the diameter at right angle to it (measured in mm.).
Estimation of the serum glycoproteins.-Serum glycoproteins were estimated in
term of their non-glucosamine polysaccharide content. The procedure described
by Shetlar, Foster and Everett (1948) was followed. The steps can be briefly
summarized as follows: precipitation of the serum glycoproteins from a known
dilution of serum by absolute ethanol, treatment of the precipitate with 77%
sulphuric acid and addition of 1% tryptophan, boiling the mixture in a water
bath for 20 minutes and then cooling. The colour developed was then read in an
Evelyn photocoiorimeter, using a filter of 515 m,u, against standard solutions
made of equal known concentrations of galactose and mannose. A blank tube
contained all the chemicals. but with addition of distilled water instead of serum.
RESULTS
Experiment 1
Nineteen mice were inoculated with sarcoma 180. In order to get accurate
information about the changes in the serum glycoprotein level in relation to
tumour growth, we dealt with each animal separately; estimating on the same
day its serum glycoprotein and measuring the size of the tumour it bore. Three
of the animals were bilaterally inoculated (i.e. by two tumour implants) and 16
inoculated unilaterally.
Results are shown in Tables I, II and III.
TABLE I.-Relation Between Serum Glycoprotein and Tumoure Size in Three of the
Mice Inoculated with Sarcoma 180, Showing Typical Behaviour
Mouse 1 Mouse 2 Mouse 3
Tumour Tumour Tumour
Glycoprotein size Glycoprotein size Glycoprotein size
Day (mg.%) (mm.2) (mg.00) (mm.2) (mg.%) (mm.2)
0 . 90 1 90 1 72 1
2 . 73 8
3. 100 12 -
4 .. 145 48
6. - 96 96 -
7 171 140 147 140 . 148 96
12 . - - . 135 192
14 147 600 . 147 600 . 135 192
17 72 1200 . 7a 1200 . Died
Died Died
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TABLE II.-RClation Between Serum Glycoprotein and Tumour Size in
Two Mice in which Sarcoma 180 Spontaneously Regressed
Mouse 2
Tumour
Glycoprotein size
(mg-.%) (mm.2)
72 1
66
102
8
48
149 140
200
192
174
135
200
96
96
6
TABLE III.-Relation Between Serum Glycoprotein and Tumour Size in
Three Mice in which Sarcoma 180 Failed to Develop
Mfouse 1
Tumour
Glycoptorein size
(mg.0%) (mm.2)
90 1
72 1
60 8
150 15
300 8
205 2
13.5 2
100 0
Mouse 2
A
Tumour
Glycoprotein size
(mg.00) (mm.2)
90 1
102
128
300
192
95
(I
Mouse 3
Tumour
Glycoprotein size
(mg.00) (mm.2)
93 1
72
150
80
8
8
2
In experiment 1, 14 mice developed tumours which progressively grew till
they killed the animals. The serum glycoprotein in these mice underwent the
following changes:
(a) A slight initial fall in most of the animals in the first two or three days,
(b) Then a gradual rise, reaching a maximum between the seventh and ninth
days,
(c) Then a gradual fall which might reach normal levels in the third and fourth
weeks, while the tumours were progressively growing till the death of the animals.
Table I shows the relation between serum glycoprotein level and size of tumour
in three of the above group of mice.
Two mice developed tumours which grew to a good size, then the sarcoma 180
began to regress spontaneously. A higher level of serum glycoprotein was noticed
in these two animals, it reached 200 mg.00 and remained sustained for a time;
then declined slowly until the tumours disappeared. Results are shown in
Table II.
Mouse 1
Day
0
2
3
4
5
8
10
11
12
14
18
20
21
Glycoprotein
(mg-%)
88
72
148
194
204
147
200
96
Tumour
size
(mm.2)
1
6
35
140
140
140
140
60
Day
0
1.
_
4.
6.
8.
11
14
16
20
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In three mice, the tumours failed to grow and in spite ofthis the serum glyco-
protein reached very high levels-up to 300 mg.0%-a level which was never
reached in typically growing sarcoma 180. Results are shown in Table III.
Experiment 2
Twelve mice were inoculated with Ehrlich's ascites tumour; blood samples
were pooled from several animals each time (about 6). Results are shown in
Table IV.
TABLE IV.-Serum Glycoprotein Levels in MIice Inoculated with
Ehrlich's Ascites Tumour
Day Serum glycoprotein (mg.%o)
0 . 120
170
6 105
11 115
Results of experiment 2 are shown in Table IV; it was noticed that there was
a rise in serum glycoprotein in the early stages of growth of Ehrlich's ascites
tumour, then a fall to normal levels in the late stages.
DISCUSSION
From the above data it is evident that after inoculation of mice with sarcoma
180, the serum glycoproteins begin to rise gradually and progressively to reach a
maximum between the seventh and ninth days, then decline gradually while the
tumour is still increasing in size, and may fall to normal levels in the terminal
stages of tumour growth. The same observations are noted during the growth of
Ehrlich's ascites tumour.
Recent work has attracted inuch attention to the liver as the main source of
glycoprotein. Greenspan (1954) demonstrated that the seromucoid level was
subnormal in parenchymatous liver disease. Spiro (1958) found that the main
site of synthesis of glucosamine-which is a main constituent of serum glyco-
proteins-was the liver and that the rate of glucosamine synthesis by the liver
was much greater than by other organs such as the spleen, lungs, testicles and
kidneys. Burston, Apsey and Maclagan (1965) found an increase in liver weight
and perchloric acid soluble proteins in livers of rats, reaching a maximum 13 days
after tumour implantation.
It might be suggested that the stimulus for rapid glycoprotein production by
the liver and other organs and its elevation in the serum is the rapid proliferation
of the malignant cells; perhaps through a stimulating factor released into the
circulation by the growing neoplastic cells.
The role of raised serum glycoprotein level in malignancy is not clear. It
might be a reaction to a non-specific stress as suggested by Boas and Peterman
(1953). It might be a reaction through which the tumour tries to benefit; i.e.
the tumour stimulates the production or glycoproteins in order to utilize them in
its synthetic processes; this might be supported by finding higher concentrations
ofglycoprotein in tumours and surrounding tissues than in tissues remote from the
tumours, as reported by Catchpole (1950). However the persistently high con-
centrations of serum glycoproteins in mice in which the tumours spontaneously
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regressed and in mice in which the tumours failed to grow does not seem to support
this view.
Regarding the fall in serum glycoproteins which follows the initial rise; this
may possibly be ascribed to failure of liver and other tissues to respond to further
stimulation by the tumour. This state might represent a condition of host
exhaustion which prevails in the late stages of tumour growth.
From the present work, it appears that the estimation of serum glycoproteins
may have a diagnostic value in malignancy. Thus ifother conditions which cause
rise of serum glycoprotein level (e.g. infections) can be excluded, then the rise can
be safely attributed to malignancy.
The changes in the level of serum glycoprotein observed in the present experi-
mental work might correlate with the stage of malignant process where a rising
level would be associated with an early, and a falling level with a late stage of
malignancy. The application of this observation as a prognostic criterion in
human malignancy does not seem readily feasible owing to the fact that human
tumours generally grow at a muclh slower rate and attain a much smaller size in
relation to body weight than animal tumours, and furthermore the patient is
usually under some sort of treatment. However estimations of serum glycopro-
teins in patients at different stages oftumour growth and under various conditions
of progression and regression seem indicated with a view to exploring its value
as a prognostic criterion.
SUMMARY
Serial estimations of serum glycoprotein levels were made in mice inoculated
with sarcoma 180 and Ehrlich's ascites tumours.
The serum glycoprotein levels were found to rise gradually with the growth
of the tumour to reach a peak and then to decline slowly while the tumour was
still growing.
The origin as well as the cause of the initial rise and subsequent fall of serum
glycoproteins in relation to tumour growth are discussed, as is the possible value
of serum glycoprotein estimations in diagnosis and prognosis.
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